Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Equity (2016 - 2025)

Cytosorbents' Return on Equity history spans 14 years, with the latest figure at 2.06% for Q4 2025.

  • Quarterly results put Return on Equity at 2.06% for Q4 2025, down 134.0% from a year ago — trailing twelve months through Dec 2025 was 2.06% (down 134.0% YoY), and the annual figure for FY2025 was 1.08%, down 56.0%.
  • Return on Equity for Q4 2025 was 2.06% at Cytosorbents, down from 0.46% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.15% in Q3 2024 to a low of 2.06% in Q4 2025.
  • The 5-year median for Return on Equity is 0.41% (2021), against an average of 0.57%.
  • The sharpest move saw Return on Equity skyrocketed 133bps in 2021, then crashed -134bps in 2025.
  • Year by year, Return on Equity stood at 0.37% in 2021, then crashed by -139bps to 0.88% in 2022, then surged by 61bps to 0.35% in 2023, then tumbled by -108bps to 0.72% in 2024, then crashed by -185bps to 2.06% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 2.06%, 0.46%, and 0.33% for Q4 2025, Q3 2025, and Q2 2025 respectively.